Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07798674

TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias

Sponsor: Heidelberg University

View on ClinicalTrials.gov

Summary

Ataxias, hereditary spastic paraplegias (HSP), and spastic ataxias (collectively referred to as SPAX diseases) are rare neurological conditions that cause progressive problems with walking, balance, coordination, and daily activities. Although many SPAX diseases are caused by specific genetic changes, there is still limited knowledge about how symptoms develop over time, how fast the diseases progress, and which clinical or biological measures best reflect meaningful changes for patients. The TreatHSP Master Protocol establishes an adaptive natural history study platform designed to improve the understanding of SPAX diseases across all ages and disease stages. Within this platform, the TreatHSP/SPAX study serves as the core natural history study, providing a shared framework for long-term clinical follow-up, standardized outcome assessments, and biosample collection. Participants enrolled in TreatHSP/SPAX are followed over time to document disease progression using clinical examinations, patient- and caregiver-reported outcomes, digital movement measures, imaging, and biological samples. In addition to this core dataset, the TreatHSP Platform allows optional, disease- or hypothesis-specific substudies to be added over time in selected participant groups. These additional assessments are introduced under the same master protocol, without creating separate stand-alone studies. The overall goal of the TreatHSP Master Protocol is to generate high-quality natural history data, identify sensitive and patient-relevant outcome measures, and support the development of future therapies for ataxias, hereditary spastic paraplegias, and spastic ataxias.

Official title: TreatHSP/SPAX Master Protocol: Adaptive Platform for Longitudinal Progression, Biomarkers and Pathophysiology in Ataxias, Hereditary Spastic Paraplegias and Spastic Ataxias (TreatHSP/SPAX)

Key Details

Gender

All

Age Range

5 Years - Any

Study Type

OBSERVATIONAL

Enrollment

4000

Start Date

2024-07-16

Completion Date

2035-12-31

Last Updated

2026-09-01

Healthy Volunteers

Yes

Locations (30)

Medical University Innsbruck, Department of Neurology

Innsbruck, Austria

Centre of Hereditary Ataxias, Department of Neurology and Department of Pediatric Neurology, 2nd Faculty of Medicine, Charles University and Motol and Homolka University Hospital

Prague, Czechia

Paris Brain Institute ICM CRMR Neurogénétique, Hôpital de la Pitié-Salpêtrière Sorbonne Université UM75 Inserm U1127 CNRS UMR 7225 47 boulevard de l'Hôpital, CS21414

Paris, France

Ruhr University Bochum, Institute for Neuroinformatics (INI)

Bochum, Germany

German Center for Neurodegenerative Diseases (DZNE) Bonn University Hospital Bonn Clinic for Parkinson's, sleep and movement disorders

Bonn, Germany

German Center for Neurodegenerative Diseases (DZNE) Dresden; University Hospital Carl Gustav Carus Clinic and Polyclinic for Neurology

Dresden, Germany

University Hospital Erlangen, Department of Neurology

Erlangen, Germany

University Hospital Essen, Department of Pediatric Neurology / Institute of Human Genetics

Essen, Germany

German Center for Neurodegenerative Diseases (DZNE) Göttingen

Göttingen, Germany

University Hospital Göttingen, Department of Neurology

Göttingen, Germany

University Medical Centre Göttingen, Clinic for Paediatric and Adolescent Medicine

Göttingen, Germany

University Hospital Heidelberg, Department of Neurology

Heidelberg, Germany

Heidelberg University Hospital, Center for Child and Adolescent Medicine

Heidelberg, Germany

University Hospital Schleswig-Holstein , Department of Neurology

Kiel, Germany

German Center for Neurodegenerative Diseases (DZNE) Magdeburg, University Hospital Magdeburg, Department of Neurology

Magdeburg, Germany

German Center for Neurodegenerative Diseases (DZNE) Munich, Munich University Hospital LMU, Department of Neurology

München, Germany

Klinikum Vest GmbH, Treatment Center Knappschafts Hospital Recklinghausen, NeuroCentrum - Department of Neurology, Stroke Unit and Early Rehabilitation

Recklinghausen, Germany

University Hospital and Faculty of Medicine Tübingen, Clinic for Paediatrics and Adolescent Medicine

Tübingen, Germany

University Hospital and Faculty of Medicine Tübingen, Neurology with a Focus on Neurodegenerative Diseases

Tübingen, Germany

Tallaght University Hospital, Neurology

Dublin, Ireland

IRCCS Fondazione Stella Maris, MEDMOL - Molecular Medicine, Neurogenetics and Neuromuscular Diseases

Calambrone, Pisa, Italy

Associazione La Nostra Famiglia - IRCCS Eugenio Medea

Conegliano, TV, Italy

University of Pisa, Azienda Ospedaliero Universitaria Pisana, Neurology

Pisa, Italy

IRCCS Istituto Ospedale Pediatrico Bambino Gesù, Translational Pediatrics and Clinical Genetics

Roma, Italy

Università Cattolica del Sacro Cuore, Department of Neuroscience

Roma, Italy

Radboud university medical center - Radboundumc, University Medical Center

Nijmegen, Netherlands

University Hospital in Kraków, Neurology Clinical Department

Krakow, Poland

Hospital Sant Joan de Déu Barcelona, Neuromuscular Diseases Unit

Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron University Hospital - Neurology Department

Barcelona, Spain

University Hospital Marqués de Valdecilla-IDIVAL, Department of Neurology

Santander, Spain